Accuray Announces 500th TomoTherapy® System Installation
Milestone System to Handle Full Patient Load for New, Integrated Cancer Center in Scottsdale, Arizona
SUNNYVALE, Calif., May 22, 2014–Accuray Incorporated (NASDAQ: ARAY) announced today the installation of its 500th TomoTherapy® System at the grand opening of Palo Verde Cancer Center – Scottsdale in Scottsdale, Ariz. The System, a TomoHDA™ model, is the only radiation therapy device at the new center, which also offers medical oncology services. The center’s decision to invest in the latest TomoTherapy offering reflects growing confidence industry-wide in the enhanced performance and clinical versatility of the technology, long-known for its superior radiation therapy delivery, precision and treatment quality.
“Our latest innovations in TomoTherapy technology, from faster treatment planning to more efficient treatment delivery, make it the ideal solution for fully-integrated cancer centers such as the Palo Verde Cancer Center – Scottsdale,” said Joshua H. Levine, president and chief executive officer of Accuray. “We are pleased to partner with the Palo Verde team in making this important technology an option for all their patients.”
The TomoHDA System offers fast, reliable, accurate and flexible treatment planning and delivery for each patient, regardless of the location, size and complexity of the tumor. It is an ideal option for treating a wide range of cancers, including recurrent disease in patients who have already received maximum radiation doses to critical organs.
“We analyzed all radiation therapy offerings when planning our new, fully-integrated cancer center, and chose the TomoHDA System for its outstanding speed, performance and simplicity,” said Dr. Lauren Stegman, Medical Director of Radiation Oncology at Palo Verde Cancer Center – Scottsdale. “We wanted technology that would allow us to treat the broadest range of patients, and we find TomoHDA treatment planning to be flexible and easy-to-use. After working with older TomoTherapy equipment for nearly a decade and with the Accuray CyberKnife System at our affiliate site, the Phoenix CyberKnife and Radiation Oncology Center, we are confident that this next generation TomoHDA technology will allow us to treat more patients effectively. The System is the perfect complement to our existing treatment offerings and will further ensure we won’t have to turn away any difficult-to-treat patients.”
About TomoTherapy TomoHDA
The TomoHDA System sets a new standard in radiation oncology, with helical and direct-angle delivery of image-guided 3D conformal and intensity-modulated radiation therapy. With the new VoLO™ Treatment Planning and TomoEDGE™ Dynamic Jaws technologies, the TomoHDA System significantly improves workflow and delivery efficiency, while also further improving treatment quality.
More than 1,500 papers, posters and abstracts have been published on the application of the TomoTherapy System across a variety of clinical indications including breast, lung, head and neck, and prostate cancers, globally. The emergent body of evidence demonstrates the inherent advantages of the technology’s CT scanner-based platform compared to conventional radiotherapy systems.
For more information about the 500th TomoTherapy install, please email [email protected] or follow us on Twitter at @Accuray and @tomo4patients for more updates.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com/.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, trends in industry confidence and market acceptance, clinical experience, clinical applications, clinical performance, clinical results, patient treatment times and outcomes, and the company’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K, which was filed on August 29, 2013, the company’s reports on Form 10-Q, which were filed on November 8, 2013, February 7, 2014 and May 7, 2014, and as updated periodically by the company’s other filings.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.